Sandoz Gets Third Approval for FOB in Europe

Sandoz has received final European Commission (EC) approval for its version of filgrastim, a follow-on biologic (FOB) of Amgen’s human granulocyte colony-stimulating factor Neupogen. Filgrastim is indicated for the treatment of neutropenia, a blood condition associated with chemotherapy, bone marrow transplants and advanced HIV infections. This is the third EC approval of the company’s FOB, and Sandoz is the only company with marketing authorization for more than one biosimilar medicine, according to a company statement.
Generic Line